LONDON--(BUSINESS WIRE)--Technavio’s latest report on the global cancer monoclonal antibodies (mAbs) market provides an analysis of the most important trends expected to impact the market outlook from 2017-2021. Technavio defines an emerging trend as a factor that has the potential to significantly impact the market and contribute to its growth or decline.
Monoclonal antibodies are produced by using genetic engineering techniques, and they target antigens in cells, tissues, and organs. They display excellent efficacy and repeatability in clinical applications to treat various diseases with minimal side effects. Their mechanism of action, the absence of generic pathway, and therapeutic applications distinguish them from other targeted therapeutics.
F. Hoffman-La Roche is the leader in cancer mAbs market, holding a 53.83% market share. The company has an established presence in the global cancer mAbs market with products such as Avastin, PERJETA, KADCYLA, MabThera/Rituxan, Herceptin, and GAZYVA/Gazyvaro. Other vendors with competitive antibodies are expected to emerge in the market during the forecast period, providing a competitive market space.
Request a sample report: http://www.technavio.com/request-a-sample?report=55469
Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.
The top three emerging trends driving the global cancer mAbs market according to Technavio healthcare and life sciences research analysts are:
- Emergence of targeted and combination therapies
- Joint ventures and partnerships for R&D
- Advent of biosimilars expected to improve treatment rates
Emergence of targeted and combination therapies
“Targeted and combination therapies exploit the surface markers or properties specific to diseased or infected cells. These therapies are being increasingly developed for the treatment of cancers and inflammatory diseases as they cause very few or no adverse side effects. Additionally, they target multiple pathways, which reduces the risk of developing treatment-resistant disorders, thus making them a highly desirable treatment option,” says Sapna Jha, one of the lead market analysts at Technavio for oncology research.
Oncologists in both the US and Europe show a clear preference for the use of YERVOY in combination with Temodar or Zelboraf or the generic Dacarbazine in the treatment of advanced melanoma. Also, RG7446 in combination with chemotherapy plus atezolizumab, venetoclax in combination with obinutuzumab, RG7446 in combination with Avastin plus atezolizumab, among others, are currently under the Phase III of clinical testing for the treatment of various types of cancer. The approval of these therapies during the forecast period is expected to have a positive impact on the market.
Joint ventures and partnerships for R&D
Vendors are forming strategic alliances to co-develop, license, and commercialize mAbs globally. Such ventures are extremely beneficial as they enable the utilization of expertize and equipment of both the companies to develop and market novel, highly efficient drugs. They also ensure a constant inflow of investments to ensure the research is not interrupted, thus ensuring timely delivery of products.
Seattle Genetics collaborated with Bristol-Myers Squibb to develop a combination of OPDIVO and ADCETRIS to treat hematologic malignancies. Similarly, Vectibix, which was developed by Amgen, is now marketed in collaboration with Takeda Pharmaceuticals in Japan. Such practices ensure not only good returns for the vendors, and in-turn the market, but also ensures quick access to these much needed drugs to the customer base.
Advent of biosimilars expected to improve treatment rates
“The growing demand for quality care has led to the increased use of cancer mAbs. Countries worldwide are under pressure to address this demand without adding a financial burden to the patients. mAb biosimilars will play a prominent role in this scenario as they have identical active pharmaceutical ingredients to their originator biologic compounds,” says Sapna.
Biosimilars are widely preferred as they are less expensive than biologics, which ensures higher accessibility. The patent expiry of branded biologics, which are very expensive, will lead to the emergence of their biosimilars such as ABP 215 (biosimilar bevacizumab) and ABP 980 (biosimilar trastuzumab) during the forecast period. The demand for these drugs is very high, ensuring a healthy revenue for the market.
Browse Related Reports:
- Global Breast Cancer Monoclonal Antibodies Market 2016-2020
- Global Monoclonal Antibodies Market 2016-2020
- Global mAb Biosimilars Market 2016-2020
Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like cardiovascular devices, medical imaging, and patient monitoring devices. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.
Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.
Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.
If you are interested in more information, please contact our media team at email@example.com.